Thirty elderly patients with T3 or T4 breast cancer underwent a wedge biopsy for radioligand-binding assay (RLA) of oestrogen receptor (ER) activity. A second, separate group of 21 elderly patients with T3 and T4 breast cancers underwent fine needle aspiration biopsy (FNA) for imunocytochemical assay of ER (ER-ICA). AU the women received tamoxifen as primary treatment and response was assessed by UICC criteria. Tumour ER concentration by RLA was correlated with both response (Spearman's R = + 0.52) and time to progression (R = + 0.76). Nine patients with receptor-rich tumours (> 100 fmol/mg protein) failed to show a response. However, the percentage of ceUs staining for ER by ER-ICA assay was much more strongly related to the likelihood of response (R = + 0.89); no patient with < 20% cells staining responded. Wedge biopsy and the biochemical determination of ER activity is of limited value in predicting the likely response to tamoxifen; ER-ICA assays on such tumours may be more informative.
Introduction
The primary treatment of elderly women with tamoxifen is becoming an increasingly popular form of treatment.' It is well tolerated by a group of patients who may prefer to avoid operation and who frequently have concurrent diseases, which increase the risks at surgery. However, recent studies have suggested that a significant proportion of such women will fail to respond to treatment with tamoxifen and that they might benefit from alternative therapy.2 '3 The anti-oestrogen tamoxifen is thought to act through the oestrogen receptor. 4 In younger women, measurements of oestrogen receptor activity on wedge biopsies have been shown to be particularly helpful in the selection of likely responders and avoidance of unnecessary persistence with endocrine treatment in those in whom response is unlikely.' In elderly women, however, breast cancers are more likely to be oestrogen receptor-positive6'7 and endocrine-responsive than those occuring in women of younger age groups.6 '8 Here we have shown that, for elderly women with breast cancer, a standard biochemical method for assessing oestrogen receptor activity is of limited value in predicting response to tamoxifen by comparison with the results of previously reported studies of immunocytochemical staining for the receptor.9"0 Methods Between 1980 and 1986, increasing numbers of elderly women were treated primarily with tamoxifen alone. Prior to treatment, a wedge biopsy was carried out in 30 such women (aged 70 years of age or over at presentation), with T3 (5) or T4 (25) breast carcinomas, so as to obtain histological confirmation of malignancy and define oestrogen receptor status. The response to tamoxifen was retrospectively assessed according to UICC criteria. Progression was defined by a 25% or greater increase in the size ('area') of tumour and response by a reduction in size of 50% or greater."
Oestrogen receptor assays were carried out by ligand-binding assay as described previously,'2"3 care being taken that all the wedge biopsies were transferred rapidly to the laboratory on ice. A representative portion was selected for assay by an experienced pathologist, and prior to assay, a further 50 ltm section was taken and fixed to provide histological confirmation that the portion assayed contained breast cancer. 4 The second cohort of 21 elderly women with T3 and T4 tumours, presenting between 1986 (Figure 2a and b) . Twenty-four of the patients undergoing wedge biopsy were assessable for the time to progression (21) or duration of long-term stasis (3), and there was a strong correlation (Spearman's Rank correlation coefficient R = + 0.72, P = 0.0001; Figure 2a) . The (Table I) . The difference between the predictive capacities of these two types of assay could be partly a function of the 'cut-offs' used but, on the basis of the data presented, this seems unlikely. The ability of a FNA to sample a wider area of a heterogeneous tumour may provide a more representative biopsy and enhance the ability of the ER-ICA assay to predict response. Ideally we would have preferred to carry out these assays in parallel on the same group ofpatients. This was not possible, though we hope that such data will eventually be available from studies currently being undertaken by the department.
We conclude that by virtue of the simplicity of fine needle aspiration biopsy and the extra information concerning heterogeneity provided by the Abbott ER-ICA assay, the technique reported here of wedge biopsy and biochemical assay is not cost-effective in selecting elderly patients for treatment with tamoxifen. It seems likely that these considerations will also apply to the use of the newer alternative form of the biochemical assay, the enzyme-immuno assay (ER-EIA), which yields apparently higher values for oestrogen receptor concentration than does the ligand-binding assay used here.
